Search hospitals > North Carolina > Chapel Hill
University of North Carolina School of Medicine
Claim this profileChapel Hill, North Carolina 27514
Conducts research for Crohn's Disease
Conducts research for Post-Implantation Syndrome
Conducts research for Sickle Cell Disease
Conducts research for Coronary Syndrome
Conducts research for High Blood Pressure
52 reported clinical trials
4 medical researchers
Summary
University of North Carolina School of Medicine is a medical facility located in Chapel Hill, North Carolina. This center is recognized for care of Crohn's Disease, Post-Implantation Syndrome, Sickle Cell Disease, Coronary Syndrome, High Blood Pressure and other specialties. University of North Carolina School of Medicine is involved with conducting 52 clinical trials across 135 conditions. There are 4 research doctors associated with this hospital, such as Evan Dellon, MD, Miriam Sklerov, MD, Lauren Burke, MD, and Bradley Drummond, MD, MHS.Top PIs
Evan Dellon, MDUniversity Of North Carolina At Chapel Hill4 years of reported clinical research
Studies Eosinophilic Esophagitis
Studies Gastrointestinal Bleeding
6 reported clinical trials
5 drugs studied
Miriam Sklerov, MDUniversity of North Carolina School of Medicine1 year of reported clinical research
Studies Parkinson's Disease
Studies Dysautonomia
2 reported clinical trials
2 drugs studied
Lauren Burke, MDUNC School of Medicine4 years of reported clinical research
Studies Motor Function
Studies Cognitive Functioning
1 reported clinical trial
6 drugs studied
Bradley Drummond, MD, MHSUniversity of North Carolina, School of Medicine5 years of reported clinical research
Studies Chronic Obstructive Pulmonary Disease
Studies Bronchitis
1 reported clinical trial
2 drugs studied
Clinical Trials running at University of North Carolina School of Medicine
Chronic Obstructive Pulmonary Disease
Bronchitis
Alzheimer's Disease
Barrett's Esophagus
Motor Function
Cognitive Functioning
Contrast Media
Chronic Bronchitis
Pulmonary Disease
Obstructive Pulmonary Disease
Roflumilast vs Azithromycin
for COPD Exacerbations
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
Recruiting3 awards Phase 47 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of North Carolina School of Medicine?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.